Accueil   Diary - News   All news Valneva starts clinical testing of Lyme disease vaccine

Valneva starts clinical testing of Lyme disease vaccine

 

 

Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

 

Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccine announced that its vaccine candidate VLA15 against Lyme disease is now progressing into clinical testing (Phase I) following the Investigational New Drug application (IND) clearance from the Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in Europe (Belgium).


Read the press release